Previous studies, including two prospective studies sponsored by the National Comprehensive Cancer Network and the Blueprint Project [19, 20], have compared the sensitivity and reproducibility of different assays for detecting PD-L1 expression [21]. This evidence concerns the gene CD274 and cancer.